Worlds fastest fMRI trip

There is no such thing as pure pleasure; some anxiety always goes with it ~ Publius (Ovid)ius Naso (43 BC – AD 17)

The neuroscience writer Mo Costandi recently asked me for a comment on an article he was writing about the fMRI psilocybin (Magic Mushroom) study by Carhart-Harris and colleagues (2012). Naturally, this research generated a great deal of press attention - mostly concerning psilocybin as a potential treatment for depression - even though no data were presented on that topic.

Anyway, what did Carhart-Harris et al do in their pioneering study? Using fMRI (Arterial Spin Labelling [ASL] and BOLD) they compared brain activity in 15 individuals following a placebo (10-mL saline) and after psilocybin (2 mg in 10-mL saline). And they reported:

"...surprisingly, only decreases in cerebral blood flow and BOLD signal were seen, and these were maximal in hub regions, such as the thalamus and anterior and posterior cingulate cortex(ACC and PCC). Decreased activity in the ACC/medial prefrontal cortex (mPFC) was a consistent finding and the magnitude of this decrease predicted the intensity of the subjective effects."

Fig 1. Significant deactivation of mPFC and PCC following psilocybin

  

Looking at the pattern of results, I raised the possibility of anxiety being a confound for this profile of brain deactivation. The pattern of reduced mPFC, PCC activity has strong parallels with patterns seen in clinically anxious individuals and healthy individuals under threat. For example, Zhao et al (2007) examined the responses of clinically anxious and healthy individuals when listening to threat-related words (alternating with emotionally neutral words). Clinically anxious individuals showed mPFC, PCC deactivation and the healthy control group even more so.

Fig 2. Zhao et al: significant deactivation of MPFC & PCC

Anticipatory anxiety is also a potential confound here as the psilocybin scan always occurred after the placebo control scan - so, participants could predict that the second scan would be the trip. Several imaging studies of normal healthy individuals experiencing transient anticipatory anxiety have also reported similar deactivations to those reported by Carhart-Harris and colleagues. For example, Simpson et al (2001) found that normal subjects anticipating uncertain pain intensity (finger shock) display decreased mPFC blood flow.

Does psilocybin study itself provide information about participant anxiety? Some data appear not in the paper itself, but in the supplementary materials, where two relevant questions are posed:

• I feared losing control of my mind increased from 3.3 to 18.0% (ASL) & 3.1 to 14.6 % (BOLD)
• I felt afraid increased from 5.8 to 13.7% (ASL) & from 6.5 to 20.4% (BOLD)

So, psilocybin increased ratings for fear of losing mind by 4-5 times; and for I felt afraid doubled or nearly tripled in percentage terms.

Lack of a significant effect does not equal lack of an effect that is significant - Ratings for I felt afraid failed to reach significance - unfortunately sufficient information is not available to derive effect sizes and therefore any issue of power (given the small sample size n=15). Nevertheless in the earlier mock fMRI psilocybin study of Carhart-Harris et al (2011), they did report enough anxiety details to derive Cohen's d, which was greater than 1 - a large effect - again non-significant only because of the low power of the study (n=9).

Fig 3. Subjective intensity ratings (10=extremely intense effect) maximising in <60 secs

The world's fastest trip in a scanner? The psilocybin was administered intravenously, with a very rapid onset (see Fig 3). As the authors themselves remarked, finding deactivation was surprising -especially as others report increased activation following the oral ingestion of psilocybin (see Vollenweider & Kometer 2010), which is much slower acting (and was scanned one-hour later). Although Carhart-Harris et als participants had previously tripped (which is an issue itself, but left aside here), their history would not prepare them for zero to tripping in seconds!

An intravenously administered dose of psilocybin, an anticipated trip that maximises in seconds and left alone in an fMRI scanner ~ anxiety-provoking? It seems quite likely that people experienced anticipatory anxiety and anxiety during the scan itself. And most importantly, both types of anxiety are associated with the functional imaging profile documented by Carhart-Harris et al. Nobody denies the effect of psilocybin on the brain, the how much is 'trip' and how much is 'trip anxiety'.

References

A video of Carhart-Harris talking about the work

Carhart-Harris RL, Williams TM, Sessa B, Tyacke RJ, Rich AS, Feilding A, Nutt DJ (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci. 109:2138-2143


Carhart-Harris RL; Williams TM; Sessa B; Tyacke RJ; Rich AS; Feilding A; Nutt DJ. (2011). The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability. J Psychopharmacol. 25:1562-1567

Simpson JR Jr, Drevets WC, Snyder AZ, Gusnard DA, Raichle ME (2001): Emotion-induced changes in human medial prefrontal cortex: II. During anticipatory anxiety. Proc Natl Acad Sci 98:688–693.


Vollenweider FX and Kometer M (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11: 642–651Nat Rev Neurosci 11: 642–651

Zhao, X.H., Wang, P.J., Li, C.B., Hu, Z.-H., Xi, Q., Wu,W.-Y., Tang, X.-W., (2007). Altered default mode network activity in patients with anxiety disorders: an fMRI study. Eur. J. Radiol. 63, 373–378.

Whats Your Poison - LSD vs Alcohol

"A single dose of LSD, in the context of various alcoholism treatment programs, is associated with a decrease in alcohol misuse"

This was the remarkable conclusion from a meta-analysis just published by Krebs & Johansen (of the Norwegian University of Science and Technology in Trondheim). Their paper forms part of an intriguing renewed interest in using psychedelic drugs as therapeutic agents and is the first attempt to draw some conclusions from the wider literature through the use of meta-analysis.

Unsurprisingly, the study has received wide media attention with headlines such as LSD 'helps alcoholics to give up drinking' and claims by some, such as Professor David Nutt that:

"Overall there is a big effect, show me another treatment with results as good; we've missed a trick here…This is probably as good as anything we've got [for treating alcoholism]."

Administering LSD to alcoholics was quite popular during the late 50s until the early 70s -as partly evidenced by Krebs & Johansen locating over 4000 relevant articles in their litearture trawl. At one point, Alcoholics Anonymous founder - William Griffith Wilson - advocated dispensing LSD at AA meetings (prior to changes in LSD legality).

The Watchmen or just early members of an AA group?

So, what did Krebs & Johansen do in their analysis? After screening their 4000+ records, they whittled their meta-analysis down to just 6 randomised controlled trials.

• the 6 LSD groups consisted of 325 individuals who received single oral doses of LSD ranging from approx 210 mcg (3 mcg/kg) to 800 mcg, with a median dose of 500 mcg
• the 6 'Control' groups consisted of 211 indviduals receiving low-dose LSD (25 mcg or 50 mcg), d-amphetamine (60 mg), ephedrine sulphate (60 mg), or non-drug control conditions (TAU or sit and write for 3 hours)

Krebs & Johansen evaluated 'outcome' as the number of alcoholics who showed 'improvement' and so, for each study they calculated an odds-ratio. Overall, the odds-ratio was 1.96, indicating that compared to 'controls', those in the LSD condition were almost twice as likely to show lowered alcohol misuse. Those few studies that followed-up patients showed that any improvement was temporary.

Given the potentially huge ramifications of their conclusions, it is worth considering the Krebs & Johansen paper in more detail - so here are a few reasons why we may want to reign in the rhetoric:

1. None the 6 studies in the meta-analysis actually documented a significant impact of LSD on alcohol misuse. Pooling data from the 6 studies, however, revealed a highly significant effect (p=.0003). As the authors note, a lack of significant effects for individual studies may reflect the use of small samples and their lack of power to detect differences. Despite this, 2 of the 6 studies with seemingly quite large samples (Ludwig n=176, Pahnke n=117) still reported nonsignificant effects of LSD on alcohol misuse. The lack of effects for individual studies may well explain precisely why the practice of LSD as a therapy for alcoholism was terminated – i.e because it did not produce any noticeable effect in a single study!
2. The question now is whether a large-scale trial is warranted (to overcome the assumed low power of past studies)? Meta-analyses can produce significant effects despite most or even all individual studies being nonsignificant; and several high profile cases have appeared in other treatment literatures (e.g. streptokinase: Lau et al 1992). Crucially, when those treatments have subsequently been evaluated in definitive large trials, they have failed to reach significance. Egger and colleagues have written extensively on the unreliability of conclusions in meta-analyses where small numbers of nonsignificant trials are pooled to produce significant effects (Egger & Davey Smith. 1995) for a recent example, see Rerkasem K, Rothwell PM (2010).
3. When examining small numbers of randomised control trials with marginal effects, one particular issue is publication bias. Given the lack of significant effects in these 6 published trials, it seems feasible that other nonsignificant studies never even reached the publication stage (but languish in file drawers of researchers). Consistent with this notion, we would expect small trials to produce greater variability in the outcomes with some reporting large effects and others reporting small (negative) effects – this does not appear to be the case here – the studies were strikingly homogeneous. Unfortunately bias was not addressed in the paper

4. As the 6 studies themselves date back to 1966-1970, it has not been possible to track-down all of the original papers. Nonetheless, I draw attention to one study in the analysis (Smart et al 1966). Although Krebs & Johansen claim they excluded serious mental health problems with "contraindication for treatment with LSD" such as schizophrenia, the Smart et al study tests alcoholics with schizophrenia, organic brain syndrome, epilepsy, OCD and borderline IQ. It is difficult to know what to make of analyses of the effects of LSD in such groups and it would be useful to know if the groups in the remaining studies had similar compositions.
5. Crucially, I note an important data error in the meta-analysis. For the Ludwig et al (1969) study, Krebs & Johansen report an OR of 1.88; however, this does not correspond to the data of 88/132 and 31/44 reported (see their Figure above). This is a particular concern not just because there are only 6 studies, but because the Ludwig study contains the largest weighting in the whole meta-analysis!
6. Two studies (Hollister et al., 1969; Tomsovic and Edwards, 1970) had poor retention rates specifcially for the controls - with retention rates of 64% and 73% for controls vs. 81% and 92% for LSD. Crucially, these two studies produced the largest Odds-Ratios in favour of LSD (OR =2.27 and 2.25 respectively). Referring to these studies, Krebs & Johansen state that the "...authors of both of these trials expressed that missing participants had probably relapsed to problem alcohol use, consistent with the strategy of considering missing participants as unimproved."  In other words, Krebs & Johansen assumed that drop-outs reflected 'alcohol misuse'; and since drops outs were high for controls in these two studies, we have the largest effects!

These are only some of the issues - we could also discuss the strange control groups, which clearly are not 'controls' in our normal understanding (e.g. treatment as usual and so on), the inability of the designs to disentangle the effects of LSD from the therapy provided, or the somewhat opaque outcome measures.

Summary
While this is an intriguing re-analysis of old data, I don't think anyone should be placing any orders on the basis of this meta-analysis. The number of studies is small; given the negative findings for all individual studies, it seems quite likely that further unpublished studies exist (with even more negative results); the analysis appears to contain a potentially influential error; at least one other study contains individuals who would seem unsuitable for analysis; and far more controls were assumed to relapse simply because they dropped out of the study. So, with only 6 studies in the meta-analysis, it would seem prudent to think very carefully before offering LSD as a treatment for alcoholism just yet.

References

Egger & Davey Smith. (1995) Misleading meta-­analysis. Lessons from “an effective, safe, simple” intervention that wasn't. British Medical Journal;310:752­4

Krebs, T. S. & Johansen, P-O. (2012 in press). Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials Journal of Psychopharmacology

Rerkasem K, & Rothwell PM. (2010) Meta-analysis of small randomized controlled trials in surgery may be unreliable. British Journal of Surgery; 97: 466–469.

Smart RG, Storm T, Baker EF & Solursh L (1966) A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior. Q J Stud Alcohol 27: 469–482